Document Type : Case Report(s)
Authors
- Gokula Kumar Appalanaido 1
- Mohd Zahri Abdul Aziz 2
- Hasmah Hussin 3
- Syadwa Abdul Shukor 4
- Noor Diana Roslan 5
- Nor Hafizah Ishak 1
- Noor Khairiah A. Karim 2
- Keerthaanaa Yogabalan 1
1 Oncology and Radiotherapy Unit, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), Penang
2 Department of Biomedical Imaging, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), Penang
3 Department of Clinical Medicine, Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia (USM), Penang
4 National University Cancer Institute, Radiation Oncology
5 Faculty of Medicine, Universiti Islam Antarabangsa Sultan Abdul Halim Mu’adzam Shah
Abstract
While surgical resection of the primary tumour and regional nodes is part of the standard algorithm for the treatment of early-stage invasive breast carcinomas, not all patients are surgical candidates or agree for surgery. This case report is about one such patient who refused surgery for a biopsy confirmed in the 7th edition of the tumour, nodes, metastases (TNM) Classification System (TNM7) T2N1M0 left breast infiltrative ductal carcinoma with estrogen receptor/ progesterone receptor positive and human epidermal growth factor receptor 2 negative for personal reasons.
A 39-year-old lady presented with left breast mass at upper outer quadrant, which confirmed to be infiltrative ductal carcinoma with Luminal A sub-type from the biopsy report. Despite the early stage of breast cancer, she refused for surgery because of personal reasons. Therefore, she underwent 12 cycles of chemotherapy followed by radiotherapy to the left breast and regional nodes to a dose of 50 Gy in 25 fractions (fx) and further high dose rate (HDR) brachytherapy boost of 16 Gy in 1 fx to the 2.0 × 2.0 cm residual lesion. After the completion of the treatment, the patient was on 20 mg tablet Tamoxifen daily.
During follow-up, there was a residual fibrotic lesion in the left breast from the computed tomography scan, and there was a doubt on the nature of the lesion. Thus, the patient was subjected to excision of the lesion and regional nodes, which showed a pathological complete response of three years after the completion of HDR brachytherapy. While surgery is the standard of care, this case report shows that definitive HDR brachytherapy has a role in patients not suitable for surgery.
Highlights
Gokula Kumar Appalanaido (google scholar)
Hasmah Hussin (google scholar)
Keywords
Main Subjects
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.30476/mejc.2025.103394.2137
- Peek MCL, Douek M. Ablative techniques for the treatment of benign and malignant breast tumours. J Ther Ultrasound. 2017;5:18. doi: 10.1186/s40349-017-0097-8. PMID: 28680636; PMCID: PMC5494757.
- Shibamoto Y, Takano S. Non-surgical definitive treatment for operable breast cancer: Current status and future prospects. Cancers (Basel). 2023;15(6):1864. doi: 10.3390/cancers15061864. PMID: 36980750; PMCID: PMC10046665.
- García-Tejedor A, Guma A, Soler T, Valdivieso A, Petit A, Contreras N, et al. Radiofrequency ablation followed by surgical excision versus lumpectomy for early stage breast cancer: A randomized phase II clinical trial. Radiology. 2018;289(2):317-24. doi: 10.1148/radiol.2018180235. PMID: 30129904.
- Xia LY, Hu QL, Xu WY. Efficacy and safety of radiofrequency ablation for breast cancer smaller than 2 cm: A systematic review and meta-analysis. Front Oncol. 2021;11:651646. doi: 10.3389/fonc.2021.651646. PMID: 34012918; PMCID: PMC8126716.
- Patel RB, Baniel CC, Sriramaneni RN, Bradley K, Markovina S, Morris ZS. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy. 2018;17(6):995-1003. doi: 10.1016/j.brachy.2018.07.004. PMID: 30078541; PMCID: PMC8292980.
- Appalanaido GK, Bahajjaj SIBZ, Shukor SA, Ahmad MZ, Francis HCH. Case report-staged brachytherapy achieving complete metabolic response in unresectable oligometastatic colorectal cancer to the liver. Oxf Med Case Reports. 2021;2021(4):omab016. doi: 10.1093/omcr/omab016. PMID: 33948189; PMCID: PMC8081016.
- Shibamoto Y, Murai T, Suzuki K, Hashizume C, Ohta K, Yamada Y, et al. Definitive radiotherapy with SBRT or IMRT boost for breast cancer: Excellent local control and cosmetic outcome. Technol Cancer Res Treat. 2018;17:1533033818799355. doi: 10.1177/1533033818799355. PMID: 30222523; PMCID: PMC6141921.
- Charaghvandi RK, van Asselen B, Philippens ME, Verkooijen HM, van Gils CH, van Diest PJ, et al. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol. BMC Cancer. 2017;17(1):181. doi: 10.1186/s12885-017-3144-5. PMID: 28274211; PMCID: PMC5343419.
- Hass P, Mohnike K, Kropf S, Brunner TB, Walke M, Albers D, et al. Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy. 2019;18(6):823-8. doi: 10.1016/j.brachy.2019.08.003. PMID: 31522972.
)